Investment opportunity
A medical device company developing a product that could replace the smear test as the primary screen for cervical cancer is seeking £400,000 to complete product development.
Aperio Diagnostics Ltd was set up in 2006 by the National Health Service technology transfer company Medipex, to commercialise a handheld probe based on research from Sheffield University and Sheffield NHS Hospitals Trust.
In the current screening process cells taken from the outer opening of the cervix have to be transported to a laboratory for analysis. The company’s device uses electrical impedance to gauge whether cells are pre-cancerous. The probe is inexpensive and gives a result immediately.
Aperio Diagnostics is seeking £400,000 to fund the final stages of trials and product roll-out across the UK.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.